Keywords: roche, says, tarceva, cost-effective, study, swiss, drug

Roche says Tarceva is cost-effective in study

Article | 05 February 2007

Print This

Swiss drug major Roche says that a the results of a study indicate that its oral anticancer drug Tarceva (erlotinib), ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in